274 related articles for article (PubMed ID: 18472167)
1. Drugs for men and women - how important is gender as a risk factor for TdP?
Coker SJ
Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
3. Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology.
Jonsson MK; Vos MA; Duker G; Demolombe S; van Veen TA
Pharmacol Ther; 2010 Jul; 127(1):9-18. PubMed ID: 20462510
[TBL] [Abstract][Full Text] [Related]
4. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human.
Cheng J
Fundam Clin Pharmacol; 2006 Feb; 20(1):1-8. PubMed ID: 16448390
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in understanding sex differences in cardiac repolarization.
James AF; Choisy SC; Hancox JC
Prog Biophys Mol Biol; 2007 Jul; 94(3):265-319. PubMed ID: 15979693
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
7. Influence of steroid hormones on ventricular repolarization.
Salem JE; Alexandre J; Bachelot A; Funck-Brentano C
Pharmacol Ther; 2016 Nov; 167():38-47. PubMed ID: 27452340
[TBL] [Abstract][Full Text] [Related]
8. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
Hondeghem LM
J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in the proarrhythmic potential of QT-prolonging drugs.
Wolbrette D
Curr Womens Health Rep; 2002 Apr; 2(2):105-9. PubMed ID: 12116598
[TBL] [Abstract][Full Text] [Related]
10. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
Hashimoto K
Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
[TBL] [Abstract][Full Text] [Related]
11. [Why is QT interval interesting?].
Elming H; Sonne J; Lublin HK
Ugeskr Laeger; 2002 Feb; 164(6):750-4. PubMed ID: 11851179
[TBL] [Abstract][Full Text] [Related]
12. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
14. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
[TBL] [Abstract][Full Text] [Related]
15. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced q-T prolongation.
Kao LW; Furbee RB
Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
[TBL] [Abstract][Full Text] [Related]
17. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.
Webster R; Leishman D; Walker D
Curr Opin Drug Discov Devel; 2002 Jan; 5(1):116-26. PubMed ID: 11865665
[TBL] [Abstract][Full Text] [Related]
18. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
19. Male/female differences in pharmacology: safety issues with QT-prolonging drugs.
Anthony M
J Womens Health (Larchmt); 2005; 14(1):47-52. PubMed ID: 15692277
[TBL] [Abstract][Full Text] [Related]
20. Gender differences in autonomic modulation of ventricular repolarization in humans.
Nakagawa M; Ooie T; Ou B; Ichinose M; Takahashi N; Hara M; Yonemochi H; Saikawa T
J Cardiovasc Electrophysiol; 2005 Mar; 16(3):278-84. PubMed ID: 15817086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
